Portfolio:

Program:

Therapeutic Area:

ZymoGenetics Pipeline

	Preclinical	Phase 1	Phase 2	Phase 3	Marketed
RECOTHROM^® (recombinant human thrombin)
Surgical Bleeding
PEG-Interferon lambda
Hepatitis C
IL-21
Metastatic Melanoma
IL-31 mAb
Atopic Dermatitis

Out-licensed Product Candidates ¹

	Preclinical	Phase 1	Phase 2	Phase 3	Marketed
Atacicept Merck Serono
Systemic Lupus Erythematosus
rFactor XIII Novo Nordisk
Congenital Deficiency
Cardiac Surgery
FGF-18 Merck Serono
Cartilage Injury Repair
Osteoarthritis
IL-20 mAb Novo Nordisk
Psoriasis
IL-21 mAb Novo Nordisk
Autoimmune & Inflammation
IL-17RC Merck Serono
Autoimmune & Inflammation
IL-22RA mAb Merck Serono
Psoriasis

Out-licensed Commercial Products¹

	Preclinical	Phase 1	Phase 2	Phase 3	Marketed
Novolin^® (Insulin) and Insulin Analogs² Novo Nordisk
Diabetes
NovoSeven^® (Factor VIIa)² Novo Nordisk
Hemophilia
Regranex^® (PDGF-BB) Systagenix Wound Management
Wound Healing
GEM 21S^® (PDGF-BB) Osteohealth Co.
Periodontal Defects
GlucaGen^® (Glucagon)² Novo Nordisk & Bedford Laboratories, and Eisai Co.
Hypoglycemia
Cleactor^® (tPA analog) Eisai Co.
Myocardial Infarction
Augment^™ Bone Graft / Augment^™ Injectable Bone Graft (PDGF) BioMimetic Therapeutics
Orthopedic Fracture

Out-licensed marketed products and product candidates are fully-licensed to listed party. ZymoGenetics does not participate in the development of out-licensed product candidates. For additional information, please contact the licensee party.
ZymoGenetics does not receive any revenues, milestones or royalties for designated products.